ATHA vs. AADI, APLT, BLUE, COEP, DYAI, STTK, ELYM, ATNM, HOWL, and LVTX
Should you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Aadi Bioscience (AADI), Applied Therapeutics (APLT), bluebird bio (BLUE), Coeptis Therapeutics (COEP), Dyadic International (DYAI), Shattuck Labs (STTK), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Werewolf Therapeutics (HOWL), and LAVA Therapeutics (LVTX). These companies are all part of the "pharmaceutical products" industry.
Athira Pharma vs.
Aadi Bioscience (NASDAQ:AADI) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking, media sentiment and valuation.
Aadi Bioscience has higher revenue and earnings than Athira Pharma. Aadi Bioscience is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Athira Pharma had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 1 mentions for Athira Pharma and 0 mentions for Aadi Bioscience. Athira Pharma's average media sentiment score of 1.89 beat Aadi Bioscience's score of 0.00 indicating that Athira Pharma is being referred to more favorably in the news media.
Athira Pharma received 9 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 54.05% of users gave Athira Pharma an outperform vote while only 39.29% of users gave Aadi Bioscience an outperform vote.
Aadi Bioscience currently has a consensus target price of $1.67, suggesting a potential upside of 10.38%. Athira Pharma has a consensus target price of $13.83, suggesting a potential upside of 4,765.75%. Given Athira Pharma's higher probable upside, analysts plainly believe Athira Pharma is more favorable than Aadi Bioscience.
52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 19.8% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Athira Pharma has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Athira Pharma's return on equity.
Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 3.05, suggesting that its stock price is 205% more volatile than the S&P 500.
Summary
Athira Pharma beats Aadi Bioscience on 9 of the 15 factors compared between the two stocks.
Get Athira Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Athira Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ATHA) was last updated on 4/26/2025 by MarketBeat.com Staff
Buy ATHA Stock Free ATHA Stock Alerts